Neuphoria Therapeutics NEUP
NASDAQ NEUP
$3.76 +0.01 (+0.27%)
As of: Sep 10, 2026 · 3:59 PM EDT

Neuphoria Therapeutics (NEUP) Prepaid Assets (2023 - 2026)

Neuphoria Therapeutics' (NEUP) quarterly Prepaid Assets came in at $611913.0 in Q1 2026, up 2828.23% year-over-year from $20897.0 in Q1 2025, and up 2170.21% quarter-over-quarter from $26954.0 in Q4 2025.

Analysis

Neuphoria Therapeutics (NEUP) Prepaid Assets (2023 - 2026) Analysis & Trends

Neuphoria Therapeutics (NEUP) has reported Prepaid Assets for 4 consecutive years, with $611913.0 the latest figure, recorded in Q1 2026.

  • On a quarterly basis, Prepaid Assets rose 2828.23% year-over-year to $611913.0 in Q1 2026; TTM through Mar 2026 was $611913.0, a 2828.23% increase from a year earlier, with the FY2025 full-year figure at $740193.0, up 61.34% from the prior year.
  • Prepaid Assets was $611913.0 for Q1 2026 at Neuphoria Therapeutics, up from $26954.0 in the prior quarter.
  • Over five years, Prepaid Assets peaked at $797478.0 in Q2 2023 and troughed at $18469.0 in Q4 2024.
  • A 4-year average of $347566.2 and a median of $231108.0 in 2024 frame the typical range for Prepaid Assets.
  • Across the five-year window, Prepaid Assets sank 42.47% in 2024 and surged 2828.23% in 2026, its largest moves.
  • Over 4 years, Prepaid Assets stood at $797478.0 in 2023, then slumped by 97.68% to $18469.0 in 2024, then soared by 45.94% to $26954.0 in 2025, then jumped by 2170.21% to $611913.0 in 2026.
  • The last three Prepaid Assets figures came in at $611913.0 (Q1 2026), $26954.0 (Q4 2025), and $222319.0 (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Neuphoria Therapeutics 463.74 Mn 444.30 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 611,913.00
Dec 31, 2025 26,954.00
Sep 30, 2025 222,319.00
Jun 30, 2025 740,193.00
Mar 31, 2025 20,897.00
Dec 31, 2024 18,469.00
Sep 30, 2024 231,108.00
Jun 30, 2024 458,765.00
Jun 30, 2023 797,478.00